GlassScriptPhysician profile
Sherelen Hodges
NPI 1467947267
$2,733.86
in general payments reported to CMS, 2019-2025
15 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $506 · 2023: $250 · 2024: $1,313 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,107 · Food and Beverage: $541 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,107.00 |
| Food and Beverage | $540.96 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,777.80 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $290.00 | 2021-2025 | Tremfya |
| Abbvie INC. | $263.60 | 2021-2025 | |
| Genzyme Corporation | $112.36 | 2021-2024 | |
| Pfizer INC. | $77.98 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $37.47 | 2021-2022 | |
| Biofrontera INC. | $27.62 | 2021 | |
| Amgen INC. | $25.26 | 2021 | |
| Galderma Laboratories, L.P. | $23.50 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $19.14 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $17.86 | 2022 | |
| Epi Health, LLC | $16.61 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.63 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2023 | Sotyktu |
| Mallinckrodt Hospital Products INC. | $13.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherelen Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.